DiagnosticsNews

SRL Diagnostics launches Fatty Liver Index

The index is an algorithm-based testing for fatty liver disease

SRL Diagnostics has launched ‘Fatty Liver Index’; a first-line diagnostic test for non-alcoholic fatty liver disease. Fatty Liver Index (FLI) is an algorithm-based index that includes multiple parameters; results of GGT test (gamma-glutamyl-transferase), triglycerides test (TG), weight, height, body mass index (BMI) and waist circumference for the prediction of Non-alcoholic fatty liver disease (NAFLD).

THIS CAN BE YOUR ADVERTISEMENT

Speaking on the launch of the test, Anand K, CEO, SRL Diagnostics said, “Epidemiological studies suggest the prevalence of NAFLD is around 9 per cent to 32 per cent of the general population in India with higher prevalence in those who are overweight or obese and those with diabetes or pre-diabetes. Additionally, NAFLD has also emerged as one of the leading causes of cirrhosis, hepatocellular carcinoma and liver transplant in India. India is the first country to have added NAFLD to one of its national disease control programs by integrating it into the National Program on Prevention and Control of Cancer, Diabetes, Cardiovascular disease and Stroke by the Ministry of Health and Family Welfare. Precise diagnosis is the first step in disease control and we are proud to lead this initiative for NAFLD.”

Adding her comments, Dr Kshama Pimpalgaonkar, Head of Department, Biochemistry, SRL Diagnostics said “Fatty liver disease is a common condition caused by the storage of extra fat in the liver. NAFLD is becoming the most common chronic liver disease in the absence of little or no alcohol use or any other obvious factors for damage. It is also associated with hyperlipidemia and cardiovascular diseases. Fatty liver may not show any symptoms. When symptoms occur, they may include abdominal pain and fatigue. Early diagnosis is important due to the lack of symptoms. The test is useful for those who are at high risk for NAFLD.”

In certain cases, NAFLD may progress to nonalcoholic steatohepatitis (NASH), marked by inflammation of the liver. Persistent inflammation in the liver will cause scarring (fibrosis), if the scarring becomes widespread (cirrhosis) it may cause impaired liver function. The symptoms in such cases would be enlarged blood vessels just beneath the skin’s surface, enlarged spleen, red palms and yellowing of the skin and eyes (jaundice).

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close